Description

Bilastine

Drug Class: Second-generation H1-antihistamine

• Potent inhibitor of the histamine H1 receptor approved for the treatment of Allergic Rhinitis.
• Rapidly absorbed after oral administration with max plasma concentration achieved within one hour.
• More effective than levocetirizine and fexofenadine in controlling symptoms of SAR.
• Once-daily treatment was effective in managing symptoms and improving patients’ quality of life.

Montelukast

Drug Class: Leukotriene receptor antagonists (LTRAs)

• Orally active, highly selective cysteinyl leukotriene type-1 receptor antagonist of leukotriene D4.
• Rapidly absorbed, achieving plasma concentration in 3-4 hours.
• Exhibits efficacy similar to loratadine with an excellent safety profile.
• Keep improving the quality of life of asthma patients.
• Easy once-a-day daily administration.